Successful Bendamustine Desensitization for a Delayed-Type Hypersensitivity Reaction

Martín‐García, Cristina; Pacho, M Sierra; Rodilla, E Moreno; Melgosa, A M Callejo; Alonso, Juanjo; T, Colino; Barrio, G Acevedo Del; Valiño, Cristina; Aradas, M C Eiris

doi:10.18176/jiaci.0335

J Investig Allergol Clin Immunol

2019

DOI: 10.18176/jiaci.0335

|View full text |Cite

Successful Bendamustine Desensitization for a Delayed-Type Hypersensitivity Reaction

Cristina Martín‐García

M Sierra Pacho

E Moreno Rodilla

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bendamustine is an alkylating agent used intravenously for the treatment of refractory hematologic or other malignancies (e.g., chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma) with other agent or as monotherapy [ 1 ]. There a few reported cases where hypersensitivity reaction to this drug was reported and allergological work-up was carried out [ 2 , 3 ]. We present a case of the patient, who developed hypersensitivity reaction during treatment of CLL and bendamustine was suspected.…”

mentioning

confidence: 99%

Skin testing with bendamustine: what concentration should be used?

Malinauskienė

Černiauskas

Linauskienė

et al. 2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls underwent skin testing with the concentrations of the bendamustine described in earlier studies. We doubted the testing recommendations as all the controls developed serious local reactions. The clinical meaning of the positive skin test reaction in the patient remained unclear and questioned the safeness of recommended testing concentrations as in certain situations wrong diagnosis could be made or even harm could be done. Future investigations are needed when allergy to bendamustine is suspected.

show abstract

mentioning

confidence: 99%

Skin testing with bendamustine: what concentration should be used?

Malinauskienė

Černiauskas

Linauskienė

et al. 2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

show abstract

Bendamustine

2019

Reactions Weekly

View full text Add to dashboard Cite

Use of Rapid Drug Desensitization in Delayed Hypersensitivity Reactions to Chemotherapy and Monoclonal Antibodies

2022

View full text Add to dashboard Cite

Background:Rapid drug desensitization (RDD) allows first-line therapies in patients with immediate drug hypersensitivity reactions (DHR) to chemotherapeutic drugs (ChD) and monoclonal antibodies (mAb). Desensitization in delayed drug reactions has traditionally used slow protocols extending up to several weeks; RDD protocols have been scarcely reported.Patients and Method:We retrospectively analyzed the patients referred to the Allergy Department, who had experienced a delayed DHR (> 6 h) related to a ChD or mAb and underwent an RDD protocol. The rate of successful administration of the offending drug and the presence of adverse reactions were evaluated.Results:A total of 93 RDDs were performed in 11 patients (including 6 men and 5 women, with a median age of 61 years). The primary DHR were maculopapular exanthema (MPE) (8), generalized delayed urticaria (1), MPE with pustulosis and facial edema (1), and facial edema with desquamative eczema (1). The meantime for the onset of symptoms was 3 days (range 1–16 days). RDD was performed using a protocol involving 8–13 steps, with temozolomide (25), bendamustine (4), rituximab (9), infliximab (24), gemcitabine (23), and docetaxel (8), within 4.6–6.5 h. Sixteen breakthrough reactions were reported during the RDD (17.2 %) in 5 patients; all were mild reactions including 11 delayed and 5 immediate reactions. All patients completed their treatment.Conclusions:RDD is a potentially safe and effective procedure in patients suffering from delayed reactions to ChD and mAb. It allows them to receive full treatment in a short period, thereby reducing time and hospital visits.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Successful Bendamustine Desensitization for a Delayed-Type Hypersensitivity Reaction

Cited by 3 publications

References 7 publications

Skin testing with bendamustine: what concentration should be used?

Skin testing with bendamustine: what concentration should be used?

Bendamustine

Use of Rapid Drug Desensitization in Delayed Hypersensitivity Reactions to Chemotherapy and Monoclonal Antibodies

Contact Info

Product

Resources

About